The top 20 pharmaceutical companies have implemented a raft of new initiatives in the last two years. Yet in two important areas, progress remains static.

› Go to Key Findings

The industry pipeline is concentrated on five diseases. Five companies are developing more than half the products for developing countries.

› Go to Key Findings

Half of the companies in the Index are developing medicines tailored for children, with 7% of the overall research pipeline being devoted to “child-size” medicine.

› Go to Key Findings

More companies are tailoring their prices to different segments of national populations.

› Go to Key Findings


New Article

Download the report

Download the report

2014 Index Ranking

Latest News

Access to Vaccines Index: the data is in, analysis can begin

10 June 2016 |

The Access to Vaccines Index will analyse how vaccine companies are improving access to high-priority vaccines for communities in need.

› Read more

Ongoing dialogue: with Japanese pharma industry and at OECD Responsible Business Forum

3 June 2016 |
From June 6–9, Executive Director, Jayasree K. Iyer, will be in Tokyo to follow up on the Foundation’s recent dialogue with Japanese pharmaceutical companies, and to meet with representatives of Japanese Government Ministries. › Read more

The Access to Medicine Foundation at the 69th WHO World Health Assembly

20 May 2016 |
The WHO’s annual World Health Assembly (WHA) draws the greatest minds working on global health. This year, Jayasree K. Iyer, Executive Director, together with Research Programme Manager Tara Prasad, will be joining on behalf of the Access to Medicine Foundation.› Read more

Data collection in progress for the 2016 Access to Medicine Index

26 April 2016 |

The world’s top 20 pharmaceutical companies are now submitting data for the 2016 Access to Medicine Index, on the measures they are taking to improve access to medicine.

› Read more

Independent evaluation finds that the Access to Medicine Index is a catalyst and inspiration for stronger action by pharmaceutical companies

9 March 2016 |

An independent, third party evaluation found that the Access to Medicine Index has made commendable contributions towards advancing the engagement of the pharmaceutical industry with the issue of access to medicine.

› Read more

What Leaders Say

Dr. Margaret Chan
Director-General, World Health Organization
"The Access to Medicine Index is a very important project. What gets measured, gets done."
Bill Gates
Chairman of Microsoft Corporation, Co-Chair and Trustee of the Bill & Melinda Gates Foundation
"When I talk to executives from pharmaceutical companies they tell me that they want to do more for neglected diseases, but they at least need to get credit for it. The Access to Medicine Index does exactly that."
Justine Greening
Justine Greening
The Rt Hon Justine Greening MP, Secretary of State for International Development, UK
"This year’s index shows that the pharmaceutical industry has made progress in improving access to vital medicines for the globe’s poorest people, helping to tackle some of the world’s worst diseases. The deadly Ebola outbreak reminds us that there is still much to be done to stop the spread of diseases in developing countries."
Lilianne Ploumen
Minister for Foreign Trade and Development Cooperation, the Netherlands
“The Access to Medicine Index mobilizes the strength of the private sector, impacting the lives of millions of the most vulnerable people on earth. It showcases the synergy of aid, trade and investment.”
Knut Kjaer
Former CEO of RiskMetrics Group, Former CEO of Norges Bank Investment Management (NBIM) (1997-2007)
"Companies are beginning to understand that the value of corporate social responsibility programmes is not only the opportunity to do the right thing but that it's good for business as well. The Access to Medicine Index provides companies with a chance to improve performance and explore new business models while helping societies in need."

In the Media

Jayasree K. Iyer featured in The Medicine Maker Power List 2016

29 April 2016 |

Jayasree K. Iyer, Executive Director at the Access to Medicine Foundation was featured as one among the top 100 influential people in the world of drug development and manufacture, as published by The Medicine Maker in their Power List 2016

› Read more

Jayasree K. Iyer comments in the Special Report on Vaccines in the Financial Times.

25 April 2016 |

In the special report on vaccines titled, Vaccines are among big pharma's best selling products published in the Financial Times, Jayasree K. Iyer comments on Sanofi’s new vaccine for dengue fever and the need for Sanofi to plan to create wide access for it.

› Read more

ETicaNews interviews Damiano De Felice on big pharma & access to medicine

8 April 2016 |

Damiano De Felice, Deputy Director of Strategy at the Access to Medicine Foundation speaks to ETicaNews on how inclusive and sustainable business models of pharmaceutical companies help facilitate access to medicine.

› Read more

Jayasree K. Iyer comments on what GSK's new patent policy means for the developing world on Nature

5 April 2016 |

In the article, Jayasree K. Iyer comments on the effect of GSK's move on other companies with bigger cancer portfolios. 

› Read more

Jayasree K. Iyer comments on GSK’s approach to IP and Patents on Access to Medicine in the Financial Times

1 April 2016 |

Jayasree K. Iyer shares her views on the announcement made by Sir Andrew Witty regarding GSK's “graduated approach” to Intellectual Property and Patents. She also discusses the overall impact of the approach on the pharmaceutical industry.

› Read more